Table 4 Secondary outcomes, adherence and beliefs about medicines

Adherence measures for CL drugs

Participants prescribed CL drug, n (%)

140 (92.1)

148 (94.9)

Participants with a positive combined adherence measure, n (%)

101 (87.8)

103 (77.4)

10.4 (1.1 to 19.7)

.033

 Eligible participants, n

115

133

MMAS-8 score (SD)

7.6 (0.8)

7.4 (1.4)

.117

MMAS-8 medium or high adherence, n (%)

106 (93.8)

115 (89.8)

3.9 (-2.9 to 10.9)

.267

 Eligible participants, n

113

128

Participants who refilled a prescription for CL drug, n

132

127

 As a proportion of those with prescription, %

94.3

85.8

8.5 (1.7 to 15.3)

.017

 As a proportion of total study group, %

86.8

81.4

5.4 (-2.7 to 13.6)

Participants with PDC 0–15 months ≥ 80%, n (%)

116 (83.6)

112 (79.5)

1.3 (0.8 to 2.4)

.376

PDC 0–15 months, mean (SD)

89.6 (12.6)

89.1 (13.8)

 Eligible participants, n

134

146

Refill adherence measure for ASA, BB, RAASi

Participants who refilled a prescription for ASA, n

133

134

 As a proportion of those with prescription, %

97.1

91.2

5.9 (0.5 to 11.3)

.036

Participants who refilled a prescription for BB, n

120

121

 As a proportion of those with prescription, %

91.6

90.3

1.3 (-5.6 to 8.2)

.711

Participants who refilled a prescription for RAASi, n

123

129

 As a proportion of those with prescription, %

93.9

92.1

1.7 (-4.3 to 7.8)

.575

Beliefs about medicines

Eligible participants

126

137

Mean Necessity score (SD)

19.1 (3.1)

18.7 (3.5)

.324

Mean Concern score (SD)

11.2 (4.6)

12.5 (4.8)

.035

Mean Necessity-Concern differential (SD)

7.9 (5.7)

6.3 (5.8)

.022

BMQ-S attitudinal category

.340

 Accepting, n (%)

79 (62.7)

81 (59.1)

 Ambivalent, n (%)

34 (27.0)

35 (25.5)

 Indifferent, n (%)

11 (8.7)

13 (9.5)

 Skeptical, n (%)

2 (1.6)

8 (5.8)